Abstract
Background Staphylococcus aureus is a major bacterial pathogen in humans, and a dominant cause of severe bloodstream infections. Globally, antimicrobial resistance (AMR) in S. aureus remains challenging. While human risk factors for infection have been defined, contradictory evidence exists for the role of bacterial genomic variation in S. aureus disease.
Methods To investigate the contribution of bacterial lineage and genomic variation to the development of bloodstream infection, we undertook a genome-wide association study comparing bacteria from 1017 individuals with bacteraemia to 984 adults with asymptomatic S. aureus nasal carriage. Within 984 carriage isolates, we also compared healthcare-associated (HA) carriage with community-associated (CA) carriage.
Results All major global lineages were represented in both bacteraemia and carriage, with no evidence for different attack rates. However, kmers tagging trimethoprim resistance-conferring mutation F99Y in dfrB were significantly associated with bacteraemia-vs-carriage (p=10−8.9-10−9.3). Pooling variation within genes, bacteraemia-vs-carriage was associated with the presence of mecA (HMP=10−5.3) as well as the presence of SCCmec (HMP=10−4.4).
Among S. aureus carriers, no lineages were associated with HA-vs-CA carriage. However, we found a novel signal of HA-vs-CA carriage in the foldase protein prsA, where kmers representing conserved sequence allele were associated with CA carriage (p=10−7.1-10−19.4), while in gyrA, a ciprofloxacin resistance-conferring mutation, L84S, was associated with HA carriage (p=10−7.2).
Conclusions In an extensive study of S. aureus bacteraemia and nasal carriage in the UK, we found strong evidence that all S. aureus lineages are equally capable of causing bloodstream infection, and of being carried in the healthcare environment.
Genomic variation in the foldase protein prsA is a novel genomic marker of healthcare origin in S. aureus but was not associated with bacteraemia. AMR determinants were associated with both bacteraemia and hospital-associated carriage, suggesting that AMR increases the propensity not only to survive in hospital environments, but also to cause invasive disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Oxford NIHR Biomedical Research Centre, a Mérieux Research Grant, the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) (grant HPRU-2012-10041), and the Health Innovation Challenge Fund (a parallel funding partnership between the Wellcome Trust (grant WT098615/Z/12/Z) and the Department of Health (grant HICF-T5-358)). Computation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. Financial support was provided by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z. D.J.W. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B). D.J.W. is supported by a Big Data Institute Robertson Fellowship. B.C.Y. is an NIHR Academic Clinical Lecturer, and this work was funded by a Research Training fellowship from Wellcome Trust (Grant 101611/Z/13/Z). T.E.P., D.W.C. and A.S.W. are NIHR Senior Investigators. The views expressed are those of the author(s) and not necessarily those of the NHS, PHE, the NIHR or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study of community S. aureus carriage was approved by Oxfordshire Research Ethics Committee B (08/H0605/102). Ethical approval for linkage to patient data without individual patient consent in Oxford was obtained from the South Central Ethics Committee (14/SC/1069) and the Confidentiality Group [ECC5-017(A)/2009]. Data about S. aureus bacteraemia in Oxfordshire, Brighton and Plymouth were collected for evaluations of clinical service provision. Under UK National Research Ethics Service guidance at the time this data collection constituted a service evaluation involving routinely available, non-identifying patient data and therefore not requiring research ethics committee review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequenced bacterial isolates submitted to Short Read Archive accession number PRJNA690682
Abbreviation
- Agr
- Accessory gene regulator
- AMR
- Antimicrobial resistance
- CA
- Community associated
- CC
- clonal complex
- HA
- Healthcare associated
- HMP
- Harmonic mean p-value
- MLST
- Multi locus sequence type
- MRSA
- Methicillin-resistant S. aureus
- LD
- linkage disequilibrium
- OR
- Odds ratio
- PBP
- Penicillin binding proteins
- PVL
- Panton Valentine leucocidin
- Rsp
- Repressor surface protein
- SAB
- Staphylococcus aureus bacteraemia
- S. aureus
- Staphylococcus aureus
- WGS
- Whole genome sequencing
